contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  availableLanguages
  pageUrl
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


invitation-to-the-presentation-of-bicos-interim-report-q2-2024

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

availableLanguages

pageUrl

imgUrl

description

BICO Group is active in medical technology. The company specializes in bio convergence and provides technology, products, and services for biology. With a focus on the application areas bioprinting, multi-omics, cell line development, and diagnostics, the company develops and markets technology that enables researchers to grow cells in 3D environments, conduct drug screening, and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries.

BICO Group

BICO’s Interim report for Q2 2024 will be published on Tuesday August 20, 2024, at 07:00am CEST. Following the release of the report, a telephone conference with the opportunity to ask questions...

<div class="mfn-body"><p>BICO’s Interim report for Q2 2024 will be published on Tuesday August 20, 2024, at 07:00am CEST. Following the release of the report, a telephone conference with the opportunity to ask questions will be held in English at 10:00 am CEST on the same day, with President &amp; CEO Maria Forss and CFO Jacob Thordenberg presenting the report.</p><p><strong>Information about the presentation and webcast</strong><br>The presentation will be available on BICO’s website from 09:00am CEST. <br><a rel="noopener" href="https://bico.com/investors/">https://bico.com/investors/</a></p><p>If you wish to participate via webcast, please use the link below. <a rel="noopener" href="https://ir.financialhearings.com/bico-q2-report-2024/register">https://ir.financialhearings.com/bico-q2-report-2024/register</a></p><p>If you wish to participate via teleconference, please register on the link below.<br>After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via teleconference.&nbsp;<br><a rel="noopener" href="https://conference.financialhearings.com/teleconference/?id=5002813">https://conference.financialhearings.com/teleconference/?id=5002813</a> </p></div><div class="mfn-footer mfn-3bedbe434cfb"><p><strong class="mfn-heading-1">For further information, please contact:</strong><br>Jacob Thordenberg, CFO, BICO Group AB<br>Phone: +46 735 34 88 84<br>E-mail:&nbsp;<a rel="noopener" href="mailto:jt@bico.com">jt@bico.com</a></p></div><div class="mfn-footer mfn-016007b7c962"><p><em>The information was submitted for publication, through the agency of the contact person set out above, on August 6, 2024 at 7.00am CEST.</em></p></div><div class="mfn-footer mfn-about mfn-e8089670866c"><p><strong class="mfn-heading-1">About BICO</strong><br>BICO is a leading provider of life science solutions and laboratory automation that enable more efficient development of new treatments with more specificity and less need for animal testing.</p><p>The company uses bioconvergence as its operating system, combining advanced technologies with biology to streamline and automate workflows within the pharmaceutical and biopharma industries.</p><p>With 46,000+ instruments installed in over 65 countries, BICO products and solutions are found in more than 3,500 laboratories, including the world’s top 20 pharmaceutical companies, and have been cited in over 12,000 publications.</p><p>Operating through three business areas – Bioprinting, Biosciences and Bioautomation – the BICO Group strives towards the long-term ambition of&nbsp;enabling the&nbsp;reduction of the world’s organ shortage and speeding up drug development to create the future of life-saving treatments.</p><p>BICO is listed on Mid-Cap, Nasdaq Stockholm under BICO. <a rel="noopener" href="http://www.bico.com">www.bico.com</a></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/a8d42ebc-83fb-4cea-abee-c62c40623c14/invitation-to-the-presentation-of-bicos-interim-report-q2-2024.pdf" class="mfn-generated mfn-primary">Invitation to the presentation of BICO’s interim report Q2, 2024</a></p></div>

Stay up to date with our newsletter